News & Updates

Chronic kidney disease (CKD) patients with hyperkalaemia may fare better with maintaining than discontinuing treatment with a renin-angiotensin-aldosterone system (RAAS) inhibitor, as discontinuation poses risks of higher mortality and increased cardiovascular events, according to a study.

Long-term anticoagulation therapy is often recommended for patients with atrial fibrillation (AF) to reduce their risk of stroke, but gastrointestinal bleeding (GIB) is a common complication that presents a significant challenge. Patients with a history of GIB have heightened risks of recurrent bleeding events, hence interruption or discontinuation of anticoagulants is often warranted. When and how to restart anticoagulant therapy following an episode of GIB has been debated. MIMS Doctor interviewed Dr Pipin Kojodjojo, Cardiologist and Cardiac Electrophysiologist at Asian Heart & Vascular Centre, Singapore, to gather his perspectives on how to manage anticoagulant therapy after a GIB episode.

The albumin order set restricted to patients with high-risk spontaneous bacterial peritonitis (SBP) leads to a marked decrease in the incidence of acute kidney injury (AKI) and mortality, reports a study. In addition, it has improved the suitability of albumin regimen ordered.

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressively debilitating disease with a formidable symptom burden and an average survival of 2–5 years from diagnosis. In 2019, the US Food and Drug Administration approved tafamidis (Vyndamax) as the first disease-modifying therapy for ATTR-CM. Since then, tafamidis has been approved for the treatment of ATTR-CM in over 55 countries including Japan, Australia, and Singapore. MIMS Doctor interviewed Dr Tang Hak Chiaw, consultant cardiologist at Novena Heart Centre, Singapore, about the types and clinical presentation of ATTR-CM in Singapore, and the role of tafamidis in the treatment of this often underdiagnosed and fatal disease of the heart muscle.